{"id":"NCT04752566","sponsor":"Alexion Pharmaceuticals, Inc.","briefTitle":"A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome","officialTitle":"A Phase 3, Prospective, Multicenter, Double Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Eculizumab in Patients With Guillain-Barré Syndrome (GBS)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-03-08","primaryCompletion":"2022-08-03","completion":"2022-08-03","firstPosted":"2021-02-12","resultsPosted":"2024-02-09","lastUpdate":"2025-09-08"},"enrollment":57,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Guillain-Barre Syndrome"],"interventions":[{"type":"BIOLOGICAL","name":"Eculizumab","otherNames":["Soliris"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Eculizumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a Phase 3, prospective, multicenter, placebo controlled, double blind, randomized study to investigate the efficacy and safety of eculizumab in participants with severe GBS, defined using the Hughes Functional Grade (FG) scale as progressively deteriorating FG3 or FG4/FG5 within 2 weeks from onset of weakness due to GBS.\n\nThis study will be conducted only at sites in Japan.","primaryOutcome":{"measure":"Time to First Reaching a Hughes Functional Grade (FG) Score <=1","timeFrame":"Up to Week 24","effectByArm":[{"arm":"Eculizumab","deltaMin":112,"sd":null},{"arm":"Placebo","deltaMin":168,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.8938"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":22,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":37},"commonTop":["Insomnia","Constipation","Urinary tract infection","Headache","Pneumonia aspiration"]}}